Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs methotrexate in elderly or cisplatin-ineligible SCCHN
2016-001331-12Phase 2Terminated
- Sponsor
- AIO-Studien
- Start
- Dec 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC) and Cervicofacial Cancer (2 arms), sponsored by AIO-Studien. Primary endpoint: overall survival (OS) rate at 1 year. Started Dec 2016; status: terminated.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Cervicofacial Cancer
Beyond the preview
Go deeper on 2016-001331-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001331-12.